Clinical and pathological associations with p53 tumour-suppressor gene mutations and expression of p21WAF1/Cip1 in colorectal carcinoma

British Journal of Cancer

Volumn 74, Issue 2, 1996, Pages 165-171

  Slebos, R J C ^a   Baas, I O ^a,b   Clement, M ^a   Polak, M ^a   Mulder, J W ^a,b   Van Den Berg, F M ^a   Hamilton, S R ^b   Offerhaus, G J A ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CIP1; Colorectal carcinoma; p21; p53 tumour suppressor; WAF1

Indexed keywords

PROTEIN P21; PROTEIN P53;

ADULT; AGED; ANEUPLOIDY; ARTICLE; CHROMOSOME 17P; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; EXON; FEMALE; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; ONCOGENE RAS; POINT MUTATION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; AGED; ALLELES; CHROMOSOMES, HUMAN, PAIR 17; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA, NEOPLASM; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; GENES, RAS; HETEROZYGOTE; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; MALE; MUTATION; TUMOR MARKERS, BIOLOGICAL;

EID: 0030037868     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.333     Document Type: Article

References (42)

1. AUVINEN A, ISOLA J, VISAKORPI T, KOIVULA T, VIRTANEN S AND HAKAMA M. (1994). Overexpression of p53 and long-term survival in colon carcinoma. Br. J. Cancer, 70, 293-296.
2. BAAS IO, MULDER JWR, OFFERHAUS GJA, VOGELSTEIN B AND HAMILTON SR. (1994). An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J. Pathol., 172, 5-12.
3. BAAS IO, VAN DEN BERG FM, MULDER JWR, CLEMENT MJ, SLEBOS RJC, HAMILTON SR AND OFFERHAUS GJA. (1996). False positive results with antigen enhancement for immunohistochemistry of the p53 gene product in colorectal neoplasms. J. Pathol. (in press).
4. BAKER SJ, FEARON ER, NIGRO JM, HAMILTON SR, PREISINGER AC, JESSUP JM, VANTUINEN P, LEDBETTER DH, BARKER DF AND NAKAMURA Y. (1989). Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science, 244, 217-221.
5. BAKER SJ, PREISINGER AC, JESSUP JM, PARASKEVA C, MARKOWITZ S, WILLSON JK, HAMILTON SR AND VOGELSTElN B. (1990). p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res., 50, 7717-7722.
6. BELL SM, SCOTT N, CROSS D, SAGAR P, LEWIS FA, BLAIR GE, TAYLOR GRD AND QUIRKE P. (1993). Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology, 104, 57-64.
7. BORING CC, SQUIRES TS AND TONG T. (1991). Cancer Statistics 1991. Ca, 41, 19-36.
8. CAMPO E, DE LA GALLE-MARTIN O, MIQUEL R, PALACIN A, ROMERO MF, VIVES J, CARDESA A AND YAGUE J. (1991). Loss of heterozygosity of p53 gene and p53 protein expression in human colorectal carcinomas. Cancer Res., 51, 4436-4442.
9. CRIPPS KJ, PURDIE CA, CARDER PJ, WHITE S, KOMINE K, BIRD CC AND WYLLIE AH. (1994). A study of stabilisation of p53 protein versus point mutation in colorectal carcinoma. Oncogene, 9, 2739-2743.
10. CUNNINGHAM J, LUST JA, SCHAID DJ, BREN GD, CARPENTER HA, RIZZA E, KOVACH JS AND THIBODEAU SN. (1992). Expression of p53 and 17p allelic loss in colorectal carcinoma. Cancer Res., 52, 1974-1980.
11. DIGIUSEPPE JA, HRUBAN RH, OFFERHAUS GJA, CLEMENT MJ, VAN DEN BERG FM, CAMERON JL AND VAN MANSFELD ADM. (1994). Detection of K-ras mutations in mucinous pancreatic duct hyperplasia from a patient with a family history of pancreatic carcinoma. Am. J. Pathol., 144, 889-895.
12. DIGIUSEPPE JA, REDSTON MS, YEO CJ, KERN SE AND HRUBAN RH. (1995). p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am. J. Pathol., 47, 884-888.
13. DUKES CE. (1932). The classification of cancer of the rectum. J. Pathol. Bacteriol., 35, 323-332.
14. 1 arrest. Cell, 76, 1013-1023.
15. EL-DEIRY WS, TOKINO T, VELCULESCU VE, LEVY DB, PARSONS R, TRENT JM, LIN D, MERCER WE, KINZLER KW AND VOGELSTEIN B. (1993). Waf1, a potential mediator of p53 tumor suppression. Cell, 75, 817-825.
16. EL-DEIRY WS, TAKAHASHI T, WALDMAN T, OLINER JD, VELCULESCU VE, BURRELL M, HILL DE, HEALY E, REES JL, HAMILTON SR, KINZLER KW AND VOGELSTEIN B. (1995). Topological control of p21WAF/CIP1 expression in normal and neoplastic tissues. Cancer Res., 55, 2910-2919.
17. FREBOURG T, KASSEL J, LAM KT, GRYKA MA, BARBIER N, ANDERSEN TIB AND FRIEND SH. (1992). Germ-line mutations of the p53 tumour suppressor gene in patients with high risk for cancer inactivate the p53 protein. Proc. Natl Acad. Sci. USA, 89, 6413-6417.
18. HALEVY O, MICHALOVITZ D AND OREN M. (1990). Different tumor-derived p53 mutants exhibit distinct biological activities. Science, 250, 113-116.
19. HALEVY O, NOVITCH BG, SPICER DB, SKAPEK SX, RHEE J, HANNON GJ, BEACH D AND LASSAR AB.(1995). Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science, 267, 1018-1021.
20. HAMELIN R, JEGO N, LAURENT-PUIG P, VIDAUD M AND THOMAS G. (1993). Efficient screening of p53 mutations by denaturing gradient gel electrophoresis in colorectal tumors. Oncogene, 8, 2213-2220.
21. HAMELIN R, LAURENT-PUIG P, OLSCHWANG S, JEGO N, ASSELAIN B, REMVIKOS Y, GIRODET J, SALMON RJ AND THOMAS G. (1994). Association of p53 mutations with short survival in colorectal cancer. Gastroenterology, 106, 42-48.
22. HARPER JW, ADAMI GR, WEI N, KEYOMARSI K AND ELLEDGE SJ. (1993). The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75, 805-816.
23. HOLLSTEIN M, SIDRANSKY D, VOGELSTEIN B AND HARRIS CC. (1991). p53 mutations in human cancers. Science, 253, 49-53.
24. KAKLAMANIS L, GATTER KC, MORTENSEN N, BAIGRIE RJ, HERYET A, LANE DP AND HARRIS AL. (1993). p53 expression in colorectal adenomas. Am. J. Pathol., 142, 87-93.
25. KERN SE. (1994). p53: tumor suppression through control of the cell cycle. Gastroenterology, 106, 1708-1711.
26. KERN SE, FEARON ER, TERSMETTE KW, ENTERLINE JP, LEPPERT M, NAKAMURA Y, WHITE R, VOGELSTEIN B AND HAMILTON SR. (1989). Clinical and pathological associations with allelic loss in colorectal carcinoma. JAMA, 261, 3099-3103.
27. KESSIS TD, SLEBOS RJC, HAN SM, SHAH K, BOSCH X, MUNOZ N, HEDRICK L AND CHO KR. (1993). p53 gene mutations and mdm2 amplification are uncommon in primary carcinomas of the uterine cervix. Am. J. Pathol., 143, 1398-1405.
28. KNUDSON A. (1971). Mutation and cancer: Statistical study of retinoblastoma. Proc. Natl Acad. Sci USA, 68, 820-823.
29. LEVINE AJ. (1992). The p53 tumor-suppressor gene. New Engl. J. Med., 326, 1350-1352.
30. LOTHE RA, FOSSLI T, DANIELSEN HE, STENWIG AE, NESLAND JM, GALLIE B AND BORRESEN AL. (1992). Molecular genetic studies of tumor suppressor gene regions on chromosomes 13 and 17 in colorectal tumors. J. Natl Cancer Inst., 84, 1100-1108.
31. MICHIELE P, CHEDID M, LIN D, MERCER WE AND GIVOL D. (1994). Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res., 54, 3391-3395.
32. MULDER JWR, OFFERHAUS GJA, DE FEYTER EP, FLOYD JJ, KERN SE, VOGELSTEIN B AND HAMILTON SR. (1992). The relationship of quantitative nuclear morphology to molecular genetic alterations in the adenoma-carcinoma sequence of the large bowel. Am. J. Pathol., 141, 797-804.
33. MULDER JWR, BAAS IO, POLAK MM, GOODMAN SN AND OFFERHAUS GJA. (1995). Evaluation of p53 protein expression as a marker for long-term prognosis in colorectal carcinoma. Br. J. Cancer, 71, 1257-1262.
34. OFFERHAUS GJA, DE FEYTER EP, CORNELISSE CJ, TERSMETTE KW, FLOYD J, KERN SE, VOGELSTEIN B AND HAMILTON SR. (1992). The relationship of DNA aneuploidy to molecular genetic alterations in colorectal carcinoma. Gastroenterology, 102, 1612-1619.
35. PARKER SB, EICHELE G, ZHANG P, RAWLS A, SANDS AT, BRADLEY A, OLSON EN, HARPER JW AND ELLEDGE SJ. (1995). p53-independent expression of p21-Cip1 in muscle and other terminally differentiating cells. Science, 267, 1024-1027.
36. RODRIGUES NR, ROWAN A, SMITH ME, KERR IB, BOOMER WF, CANNON JV AND LANE DP. (1990). p53 mutations in colorectal cancer. Proc. Natl Acad. Sci. USA, 87, 7555-7559.
37. SCOTT N, SAGAR P, STEWART J, BLAIR GE, DIXON MF AND QUIRKE P. (1991). p53 in colorectal cancer: clinicopathological correlation and prognostic significance. Br. J. Cancer, 63, 317-319.
38. SRIVASTAVA S, WANG S, TONG YA, PIROLLO K, CHANG EH, OLSON DC, MARECHAL V, MOMAND J, CHEN J, ROMOCKI C AND LEVINE AJ. (1993). Several mutant p53 proteins detected in cancer-prone families with Li-Fraumeni syndrome exhibit transdominant effects on the biochemical properties of the wild-type p53 identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes. Oncogene, 8, 2353-2360.
39. STARZYNSKA T, BROMLEY M, GHOSH A AND STERN PL. (1992). Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br. J. Cancer, 66, 558-562.
40. VAN DEN BERG FM, TIGGES A, SCHIPPER M, DEN HARTOG-JAGER C, KROES W AND WALBOOMERS J. (1989). Expression of the nuclear oncogene p53 in colon tumours. J. Pathol, 157, 193-199.
41. VOGELSTEIN B, FEARON ER, HAMILTON SR, KERN SE, PREISINGER AC, LEPPERT M, NAKAMURA Y, WHITE R, SMITS AM AND BOS JL. (1988). Genetic alterations during colorectal-tumor development. New. Engl. J. Med., 319, 525-532.
42. ZHANG W, GRASSO L, McCLAIN CD, GAMBEL AM, CHA Y, TRAVALI S, DEISSEROTH AB AND MERCER WE. (1994). p53-independent induction of WAF1/Cip1 in human leukemia cells is correlated with growth arrest accompanying monocyte/ macrophage differentiation. Cancer Res., 55, 668-674.